Senior Analyst
ForbionCheck size: Forbion does not publish one standard current check-size range across its funds on the official site.
Sarah Neshat invests or supports investments through Forbion's published strategy: Invest globally in companies transforming human health and the bioeconomy, from company creation and early stage through growth.
World-class science, experienced teams and differentiated products capable of producing major health or planetary outcomes.
Opportunities without a strong biotechnology, health or bioeconomy basis and credible scientific evidence are less aligned.
Present the science, validation, IP, team, development and regulatory plan, market and value-inflection milestones.
No writing has been linked yet. Kit can search for posts, interviews, and fund essays worth reading before outreach.
No podcast appearances are linked yet. Ask Kit to check for interviews that reveal how this investor thinks.
Quote coverage is incomplete. Kit can look for direct comments on markets, founders, and investment criteria.
Sarah Neshat is a current Senior Analyst at Forbion, according to the firm's official roster. No additional background is inferred where the firm does not publish a biography.